Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Experience Study of Povetacicept vs Sibeprenlimab in Adults With IgA Nephropathy
NCT07890909Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Dec 2027
01
Overview
Phase 3, open-label, single-arm trial of povetacicept in immunoglobulin A nephropathy (IgAN), sponsored by Vertex Pharmaceuticals. Primary endpoint: Self-Injection Administration Questionnaire at 12 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
povetacicept
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07890909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890909.